TARO Stock Overview
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally.
Taro Pharmaceutical Industries Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$37.16|
|52 Week High||US$76.00|
|52 Week Low||US$35.80|
|1 Month Change||-7.10%|
|3 Month Change||-18.60%|
|1 Year Change||-49.75%|
|3 Year Change||-63.04%|
|5 Year Change||-67.48%|
|Change since IPO||643.20%|
Recent News & Updates
|TARO||US Pharmaceuticals||US Market|
Return vs Industry: TARO underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: TARO underperformed the US Market which returned -10.4% over the past year.
|TARO Average Weekly Movement||4.1%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: TARO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: TARO's weekly volatility (4%) has been stable over the past year.
About the Company
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic.
Taro Pharmaceutical Industries Fundamentals Summary
|TARO fundamental statistics|
Is TARO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TARO income statement (TTM)|
|Cost of Revenue||US$273.71m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.029|
|Net Profit Margin||0.19%|
How did TARO perform over the long term?See historical performance and comparison
Is Taro Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TARO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TARO's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: TARO is poor value based on its PE Ratio (1298.4x) compared to the US Pharmaceuticals industry average (20.4x).
PE vs Market: TARO is poor value based on its PE Ratio (1298.4x) compared to the US market (15.5x).
Price to Earnings Growth Ratio
PEG Ratio: TARO is poor value based on its PEG Ratio (8.2x)
Price to Book Ratio
PB vs Industry: TARO is good value based on its PB Ratio (0.8x) compared to the US Pharmaceuticals industry average (1.7x).
How is Taro Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TARO's forecast earnings growth (158.7% per year) is above the savings rate (1.9%).
Earnings vs Market: TARO's earnings (158.7% per year) are forecast to grow faster than the US market (12.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TARO's revenue (10.8% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: TARO's revenue (10.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TARO's Return on Equity is forecast to be high in 3 years time
How has Taro Pharmaceutical Industries performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TARO has a high level of non-cash earnings.
Growing Profit Margin: TARO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: TARO's earnings have declined by 48.9% per year over the past 5 years.
Accelerating Growth: TARO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: TARO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.5%).
Return on Equity
High ROE: TARO's Return on Equity (0.1%) is considered low.
How is Taro Pharmaceutical Industries's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: TARO's short term assets ($1.2B) exceed its short term liabilities ($394.8M).
Long Term Liabilities: TARO's short term assets ($1.2B) exceed its long term liabilities ($31.7M).
Debt to Equity History and Analysis
Debt Level: TARO is debt free.
Reducing Debt: TARO had no debt 5 years ago.
Debt Coverage: TARO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: TARO has no debt, therefore coverage of interest payments is not a concern.
What is Taro Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TARO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TARO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TARO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TARO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TARO has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Uday Baldota (51 yo)
Mr. Uday V. Baldota has been Director at Association for Accessible Medicines. He has been the Chief Executive Officer of Taro Pharmaceutical Industries Ltd. since August 28, 2017 and served as its Co-Chie...
Experienced Management: TARO's management team is seasoned and experienced (6.7 years average tenure).
Experienced Board: TARO's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Taro Pharmaceutical Industries Ltd.'s employee growth, exchange listings and data sources
- Name: Taro Pharmaceutical Industries Ltd.
- Ticker: TARO
- Exchange: NYSE
- Founded: 1950
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.397b
- Shares outstanding: 37.58m
- Website: https://www.taro.com
Number of Employees
- Taro Pharmaceutical Industries Ltd.
- 14 Hakitor Street
- Haifa Bay
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.